Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00637130 · ClinicalTrials.gov registry record · Phase 2
Safety and Intraocular Pressure (IOP) Lowering Efficacy of Low Dose Travoprost
A Phase 2 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 138
- Enrollment target
NCT00637130: Completed Phase 2 study, sponsored by Alcon Research.
NCT00637130 is a Phase 2 study that has completed, run by Alcon Research. The registered enrollment target is 138 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00637130, a Phase 2 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 138 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and IOP-lowering efficacy of various low dose travoprost formulations in patients with open-angle glaucoma or ocular hypertension.
Interventions
- OTHER Vehicle
- DRUG Travoprost ophthalmic solution, 0.0008%
- DRUG Travoprost ophthalmic solution, 0.001%
- DRUG Travoprost ophthalmic solution, 0.0012%
- DRUG TRAVATAN
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2007-10 |
| Phase | Phase 2 |
What the finished NCT00637130 record still lists
NCT00637130 is an interventional study that assigns participants to a tested intervention. The registered 138 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 5 interventions - of which Vehicle is the first listed.
NCT00637130 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00637130 about?
NCT00637130 is a clinical study titled "Safety and Intraocular Pressure (IOP) Lowering Efficacy of Low Dose Travoprost". The purpose of this study is to compare the safety and IOP-lowering efficacy of various low dose travoprost formulations in patients with open-angle glaucoma or ocular hypertension.
What is the current status of trial NCT00637130?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 138 participants. The study started on 2007-10.
What interventions are being tested in trial NCT00637130?
The interventions under investigation include: Vehicle (OTHER), Travoprost ophthalmic solution, 0.0008% (DRUG), Travoprost ophthalmic solution, 0.001% (DRUG), Travoprost ophthalmic solution, 0.0012% (DRUG), TRAVATAN (DRUG).
Who is sponsoring clinical trial NCT00637130?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00637130's enrollment target sits among peer trials
138 525th of 2000 higher than 1,474 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04402788 · 138 participants · Phase 2
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
- NCT04883255 · 138 participants · Early Phase 1
Cannabis Use, Cognition, and the Endocannabinoid System in HIV
- NCT05620784 · 138 participants · Phase 3
Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP
- NCT05832086 · 138 participants · Phase 2
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia